Paper Details

  1. Home
  2. Paper Details

Indirect comparison of biological treatments in refractory rheumatoid arthritis.

Author: Alegre-del ReyE, Gallego-GalisteoM, Márquez-FernándezE, Ramos-BáezJ J, Villa-RubioA

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Several biological treatments are available for rheumatoid arthritis (RA). This study compared the effectiveness of seven biological medications (adalimumab, etanercept, infliximab, abatacept, tocilizumab, golimumab, and certolizumab pegol) in patients with RA who did not respond well to previous standard medications.
Paper Details　
Original Abstract of the Article :
A number of biological treatments are available for rheumatoid arthritis. They are effective some patients but their comparative efficacy is inadequately evaluated. Our aim was to compare the efficacy of adalimumab, etanercept, infliximab, abatacept, tocilizumab, golimumab and certolizumab pegol in ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2710.2011.01292.x

データ提供：米国国立医学図書館（NLM）

Biological Treatments in Refractory Rheumatoid Arthritis: A Comparative Oasis

The quest for effective treatments in [refractory rheumatoid arthritis] is a challenging journey, often requiring a careful selection of therapies tailored to individual patients. This study explores the comparative efficacy of different [biological treatments] in [rheumatoid arthritis] patients who have failed to respond to conventional [disease-modifying antirheumatic drugs (DMARDs)], offering valuable insights for clinicians navigating this complex landscape.

The researchers conducted a systematic review of published trials, comparing the efficacy of [adalimumab], [etanercept], [infliximab], [abatacept], [tocilizumab], [golimumab], and [certolizumab pegol]. This comprehensive analysis provides a valuable framework for understanding the relative benefits and drawbacks of each treatment option, allowing clinicians to make more informed decisions about patient care.

While the study highlights the efficacy of various [biological treatments] in [rheumatoid arthritis], it also underscores the need for individual assessment and careful monitoring to ensure optimal outcomes. Each patient presents a unique challenge, and the choice of treatment should be tailored to their specific needs and circumstances.

Biological Treatments: A Diverse Oasis in the Desert of Rheumatoid Arthritis

This study offers a valuable oasis of information for clinicians seeking to manage [refractory rheumatoid arthritis], providing a comprehensive comparative analysis of different [biological treatments]. By understanding the relative efficacy and potential side effects of each option, clinicians can make more informed decisions about patient care, tailoring treatment plans to individual needs and optimizing outcomes.

Dr.Camel's Conclusion

The desert of [refractory rheumatoid arthritis] is a challenging terrain, but with the emergence of a diverse range of [biological treatments], we have a newfound opportunity to provide relief for these patients. This study offers a valuable roadmap for clinicians navigating this complex landscape, enabling them to select the most appropriate treatment option for each individual patient.

Date :
  1. Date Completed 2012-10-09
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

21831256

DOI: Digital Object Identifier

10.1111/j.1365-2710.2011.01292.x

Related Literature

Article Analysis
・Effective treatment of rheumatoid arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.